ReviewClinical pharmacology and therapeutics2021
Mechanisms and Rationale for Targeted Therapies in Refractory and Unexplained Chronic Cough.
Review in Clinical pharmacology and therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 3 syntheses or guidelines pooled it, 95 citations in OpenAlex.
- Efficacy and safety of gefapixant for chronic cough: a meta-analysis of randomised controlled trials.European respiratory review : an official journal of the European Respiratory Society · 2023Pooled it
- Modulation of transient receptor potential (TRP) channels by plant derived substances used in over-the-counter cough and cold remedies.Respiratory research · 2023Pooled it
- Efficacy of behavioral cough suppression therapy for refractory chronic cough or unexplained chronic cough: a meta-analysis of randomized controlled trials.Therapeutic advances in respiratory diseasePooled it
- Safety, Tolerability, and Pharmacokinetics of Oral Camlipixant: A Randomized First-In-Human Study Using Single and Multiple Ascending Doses.Journal of clinical pharmacology · 2026Trial
- The efficacy and safety of duloxetine in treating refractory chronic cough: a randomized clinical trial.BMC medicine · 2026Trial
- Camlipixant in Refractory Chronic Cough: A Phase 2b, Randomized, Placebo-controlled Trial (SOOTHE).American journal of respiratory and critical care medicine · 2025Trial
- Trial
- The P2X3 receptor antagonist filapixant in patients with refractory chronic cough: a randomized controlled trial.Respiratory research · 2023Trial
- Trial
- Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized Study.Clinical pharmacokinetics · 2022Trial
- Challenges and Burdens in Refractory Chronic Cough: Patients' and Physicians' Perspectives.Pulmonary therapy · 2026Review
- Diagnosis and Treatment of Refractory Chronic Cough: An American Broncho-Esophagological Association Expert Consensus Statement.The Laryngoscope · 2026Article
- Article
- Clarifying Terminology in Chronic Cough: The Evolving Role of Cough Hypersensitivity Syndrome.The clinical respiratory journal · 2026Review
- Article
- Exploratory research on drugs after lung surgery based on real-world data from the FDA adverse event reporting system database.PloS one · 2026Article
- Prospective Study of Long-Term Outcomes and the Patient Experience With Superior Laryngeal Nerve Block for Chronic Cough.The Laryngoscope · 2026Article
- Comparative Analysis of Classic and Novel Antitussives on Cough Suppression in Guinea Pigs.Pharmaceutics · 2025Article
- Melatonin inhibits the activation of microglia and cough sensitivity of guinea pigs exposed to PM2.5.Histology and histopathology · 2025Article
- Prevalence and burden of possible refractory chronic cough in four European countries.ERJ open research · 2025Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic cough, defined as a cough lasting > 8 weeks, is a common medical condition that exerts a substantial physical, mental, and social burden on patients. A subset of patients with chronic cough are troubled with a cough that persists despite optimal treatment of presumed associated common and uncommon conditions (refractory chronic cough; RCC) or in which no diagnosable cause for cough can be identified despite extensive assessment (unexplained chronic cough; UCC). Many of these patients exhibit clinical features of cough hypersensitivity, including laryngeal paresthesia, hypertussia, and allotussia. Over-the-counter cough remedies are ineffective and can lead to intolerable side effects when used for RCC/UCC, and the lack of approved treatments indicated for these conditions reflects a major unmet need. An increased understanding of the anatomy and neurophysiology of protective and pathologic cough has fostered a robust clinical development pipeline of several targeted therapies for RCC/UCC. This manuscript reviews the mechanisms presumed to underly RCC/UCC together with the rationale and clinical evidence for several targeted therapies currently under clinical investigation, including transient receptor potential channel antagonists, P2X3-receptor antagonists, voltage-gated sodium channel blockers, neuromodulators, and neurokinin-1-receptor antagonists. Finally, we provide an overview of targets that have been investigated in preclinical models of cough and other airway diseases that may hold future promise for clinical studies in RCC/UCC. Development of targeted therapies with different sites of action may foster a precision medicine approach to treat this heterogeneous, underserved patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.